Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549018 | 0.76 | NCF1 (0.39) | HTR7HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL22333200 | 0.74 | ALDH1A1 (0.43) | HTR1ADRD2HTR2AHTR2CMAPT | |
| SCHEMBL22333183 | 0.73 | HRH4 (0.42) | HTR1ADRD2HTR2AHTR2CMAPT | |
| SCHEMBL2937868 | 0.72 | MAPT (0.72) | MAPTMEN1KMT2A | |
| SCHEMBL4882642 | 0.71 | HTR6 (0.68) | — | |
| SCHEMBL4178891 | 0.70 | CKS1B (0.43) | MAPT | |
| SCHEMBL4885947 | 0.70 | HTR1A (0.38) | HTR1ADRD2HTR2AHTR2CMAPT | |
| SCHEMBL22333361 | 0.67 | ELANE (0.38) | HTR1AHTR2AHTR2CMEN1KMT2A | |
| SCHEMBL5549046 | 0.67 | KDM4E (0.35) | HTR7HTR1ADRD2MAPTKMT2A | |
| SCHEMBL7970926 | 0.67 | DHODH (0.46) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1789045-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006023400-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | HTR7 2777/4885HTR1A 3730/4885DRD2 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.